Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer

Cathcart, Mary Clare, Gately, Kathy, Cummins, Robert, Kay, Elaine, O'Byrne, Kenneth J., & Pidgeon, Graham P. (2011) Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Molecular Cancer, 10(25).

View at publisher (open access)

Abstract

Background: Thromboxane synthase (TXS) metabolises prostaglandin H2 into thromboxanes, which are biologically active on cancer cells. TXS over-expression has been reported in a range of cancers, and associated with a poor prognosis. TXS inhibition induces cell death in-vitro, providing a rationale for therapeutic intervention. We aimed to determine the expression profile of TXS in NSCLC and if it is prognostic and/or a survival factor in the disease.

Methods: TXS expression was examined in human NSCLC and matched controls by western analysis and IHC. TXS metabolite (TXB 2) levels were measured by EIA. A 204-patient NSCLC TMA was stained for COX-2 and downstream TXS expression. TXS tissue expression was correlated with clinical parameters, including overall survival. Cell proliferation/survival and invasion was examined in NSCLC cells following both selective TXS inhibition and stable TXS over-expression.

Results: TXS was over-expressed in human NSCLC samples, relative to matched normal controls. TXS and TXB 2levels were increased in protein (p < 0.05) and plasma (p < 0.01) NSCLC samples respectively. TXS tissue expression was higher in adenocarcinoma (p < 0.001) and female patients (p < 0.05). No significant correlation with patient survival was observed. Selective TXS inhibition significantly reduced tumour cell growth and increased apoptosis, while TXS over-expression stimulated cell proliferation and invasiveness, and was protective against apoptosis.

Conclusion: TXS is over-expressed in NSCLC, particularly in the adenocarcinoma subtype. Inhibition of this enzyme inhibits proliferation and induces apoptosis. Targeting thromboxane synthase alone, or in combination with conventional chemotherapy is a potential therapeutic strategy for NSCLC. © 2011 Cathcart et al; licensee BioMed Central Ltd.

Impact and interest:

29 citations in Scopus
Search Google Scholar™
27 citations in Web of Science®

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 64852
Item Type: Journal Article
Refereed: Yes
Additional URLs:
Keywords: cyclooxygenase 2, thromboxane B2, thromboxane synthase, adult, aged, apoptosis, article, cancer inhibition, cell invasion, cell proliferation, cell survival, controlled study, correlation analysis, enzyme activity, enzyme blood level, enzyme immunoassay, enzyme inhibition, enzyme mechanism, female, human, human cell, human tissue, immunohistochemistry, lung adenocarcinoma, lung non small cell cancer, major clinical study, male, overall survival, prognosis, protein expression, sex difference, tissue microarray, Western blotting
DOI: 10.1186/1476-4598-10-25
ISSN: 1476-4598
Divisions: Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
Copyright Owner: Copyright 2011 the authors
Deposited On: 27 Nov 2013 07:27
Last Modified: 13 Mar 2014 04:24

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page